07:00 , Jul 25, 2016 |  BC Week In Review  |  Financial News

Advanced Inhalation Therapies withdraws IPO

Advanced Inhalation Therapies Ltd. , Rehovot, Israel   Business: Pulmonary   Date announced: 2016-07-21   Type: IPO   Underwriter: Joseph Gunnar   Note: Advanced Inhalation Therapies withdrew its IPO.  ...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Advanced Inhalation Therapies amends IPO

Advanced Inhalation Therapies Ltd. , Rehovot, Israel   Business: Infectious, Inflammation   Date announced: 2016-01-11   Type: IPO   To be raised: Up to $11.6 million   Shares: 675,000   Price: $15   Underwriter: Joseph...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Financial News

Advanced Inhalation Therapies proposes IPO

Advanced Inhalation Therapies Ltd. , Rehovot, Israel   Business: Infectious, Inflammation   Type: IPO   To be raised: Up to $34.5 million   Shares: TBD   Price: TBD   Underwriter: Aegis Capital   Note: Advanced...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

NOxCF regulatory update

The European Commission granted Orphan Drug designation to AIT’s AIT-CF to treat cystic fibrosis (CF). The inhaled nitric oxide formulation using the company’s drug delivery system has completed a Phase IIa trial in adults with...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

NOxCureCF: Phase II started

Advanced Inhalation Therapies began an open-label, Israeli Phase II trial to evaluate NOxCureCF in CF patients ages >=10 years. Advanced Inhalation Therapies Ltd. , Rehovot, Israel   Product: NOxCureCF   Business: Pulmonary   Molecular target:...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Financial News

Advanced Inhalation Therapies completes venture financing

Advanced Inhalation Therapies Ltd. , Petah Tikva, Israel   Business: Infectious, Inflammation   Date completed: 12/5/12   Type: Venture financing   Raised: $1.3 million  ...